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Abstract
Background/objectives: We aimed to evaluate the relationship between BMI and the risk of renal disease in patients
with type 2 diabetes in the Action in Diabetes and Vascular Disease: PreterAx and DiamicroN Modiﬁed-Release
Controlled Evaluation (ADVANCE) study.
Subjects/methods: Participants were divided into six baseline BMI categories: <18.5 (underweight, n = 58); ≥18.5 to
<25 (normal, n = 2894); ≥25 to <30 (overweight, n = 4340); ≥30 to <35 (obesity grade 1, n = 2265); ≥35 to <40 (obesity
grade 2, n = 744); and ≥40 kg/m2 (obesity grade 3, n = 294); those underweight were excluded. The composite
outcome “major renal event” was deﬁned as development of new macroalbuminuria, doubling of creatinine, end
stage renal disease, or renal death. These outcomes and development of new microalbuminuria were considered
individually as secondary endpoints.
Results: During 5-years of follow-up, major renal events occurred in 487 (4.6%) patients. The risk increased with higher
BMI. Multivariable-adjusted HRs (95% CIs), compared to normal weight, were: 0.91 (0.72–1.15) for overweight; 1.03
(0.77–1.37) for obesity grade 1; 1.42 (0.98–2.07) for grade 2; and 2.16 (1.34–3.48) for grade 3 (p for trend = 0.006). These
ﬁndings were similar across subgroups by randomised interventions (intensive versus standard glucose control and
perindopril-indapamide versus placebo). Every additional unit of BMI over 25 kg/m2 increased the risk of major renal
events by 4 (1–6)%. Comparable results were observed with the risk of secondary endpoints.
Conclusions: Higher BMI is an independent predictor of major renal events in patients with type 2 diabetes. Our
ﬁndings encourage weight loss to improve nephroprotection in these patients.
Introduction
Globally, obesity is common with alarming rates of
increasing prevalence1,2. It is a key component of the
metabolic syndrome, which is also characterised by
hypertension, dyslipidaemia, and insulin resistance, and
often leads to type 2 diabetes3. Diabetes is a leading
cause of chronic kidney disease (CKD) and end-stage
renal disease (ESRD)4. In the absence of diabetes,
however, experimental and epidemiological studies
have also provided accumulating evidence that obesity
is an independent risk factor for CKD5,6, a risk medi-
ated in part through intraglomerular hypertension and
hyperﬁltration7.
Most reported observational studies have found positive
associations between being overweight or obese and kid-
ney outcomes (which include development of CKD, rapid
changes in kidney function or ESRD)8–12. However, few
have been large enough to compare people with and
without diabetes reliably9, and there remains some
uncertainty in people with diabetes as to whether higher
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body mass index (BMI) increases risk of developing
macroalbuminuria, and whether BMI–CKD associations
are mediated through differences in renal risk factors
affected by adiposity (e.g., glycemia and blood pressure).
In the present study, we aimed to evaluate the rela-
tionship between baseline BMI and major renal events
among patients with type 2 diabetes in the Action in
Diabetes and Vascular Disease: PreterAx and DiamicroN
Modiﬁed-Release Controlled Evaluation (ADVANCE)
trial (ClinicalTrials.gov number, NCT00145925). In order
to investigate potential mechanisms for any associations,
outcomes were analysed for the whole cohort and in
subgroups for those randomised to different intensities of
long-term glycaemic control and to use of placebo versus
perindopril-indapamide, an ACE-inhibitor/diuretic com-
bination drug that would be expected to reduce
glomerular hyperﬁltration.
Materials/subjects and methods
Study population
The ADVANCE study was a 2× 2 factorial randomised
controlled trial which tested the effects of intensive glucose
control using a gliclazide-MR-based regimen, and routine
blood pressure treatment using a ﬁxed-dose combination of
perindopril and indapamide, on the incidence of major
macrovascular and microvascular events in patients with type
2 diabetes. The design and clinical characteristics of partici-
pants have been published previously13–15. Brieﬂy, patients
aged 55 years or older with diabetes diagnosed at 30 years or
older with pre-existing cardiovascular disease or with at least
one risk factor for cardiovascular disease were eligible. Par-
ticipants were followed prospectively for clinical events and
had blood pressure and urinary albumin to creatinine ratio
(ACR) measured at local study clinics at 2-year, 4-year and
ﬁnal follow-up visits. The ADVANCE protocol was approved
by the Institutional Ethics Committee of each participating
centre and all participants provided written informed con-
sent before their enrolment in the trial.
Deﬁnition of BMI categories at baseline
Baseline BMI, computed as the weight in kilograms
divided by the square of the height in metres, was cate-
gorised at baseline into six categories according to the
World Health Organization classiﬁcation16: underweight
(<18.5), normal weight (≥18.5 to <25), overweight (≥25 to
<30), and obesity grade 1 (≥30 to <35), grade 2 (≥35 to
<40), and grade 3 (≥40 kg/m2).
Primary and secondary endpoints
As pre-speciﬁed in the ADVANCE protocol13, “major renal
events” were deﬁned as a composite of macroalbuminuria
(deﬁned as a urinary ACR> 300mg/g), doubling of the
serum creatinine level to at least 200 μmol/l, ESRD (deﬁned
as the need for renal-replacement therapy), or death due to
renal disease. “New cases of microalbuminuria” (deﬁned as
30<ACR ≤ 300mg/g), “Development of new macro-
albuminuria”, and “doubling of creatinine, ESRD, or renal
death”, were considered individually as secondary endpoints.
The primary endpoints were reviewed by an independent
End Point Adjudication Committee.
Statistical analyses
Clinical and biological characteristics of participants at
baseline were presented both overall and according to
BMI categories. Categorical variables were expressed as
the number of patients with the corresponding percen-
tage, and continuous variables as mean (SD), or as median
(interquartile interval) for those with a skewed distribu-
tion. Patients with missing data regarding estimated
glomerular ﬁltration rate (eGFR) and ACR at baseline
(n= 545) were excluded from the current study. Few
(n= 58; 0.6 %) patients were underweight, and so these
were also excluded from the main set of analyses,
although included in a sensitivity analysis. Cox propor-
tional hazards regression models were ﬁtted to estimate
hazard ratios (HRs), with associated 95% conﬁdence
intervals (CI), for major renal events by BMI categories,
taking normal weight as the reference group. The primary
model (model 1) adjusted for baseline age, sex, region of
origin (Asia: Philippines, China, Malaysia, and India;
established market economies: Australia, Canada, France,
Germany, Ireland, Italy, Netherlands, New Zealand,
United Kingdom; and Eastern Europe: Czech Republic,
Estonia, Hungary, Lithuania, Poland, Russia, Slovakia),
prior cardiovascular disease (deﬁned as the presence
at baseline of myocardial infarction, stroke, coronary
artery bypass graft, percutaneous transluminal coronary
angioplasty, hospital admission for unstable angina or
transient ischaemic attack), eGFR (computed by the
CKD–Epidemiology Collaboration equation)17, squared
eGFR, urinary ACR, history of ever smoking and study
allocation. In model 2 we additionally adjusted for base-
line duration of diabetes, HbA1c, systolic blood pressure,
total-cholestrol and HDL-cholesterol, and triglycerides.
Since these are factors that BMI can be expected to affect
causally, most results presented are from model 1. We
also evaluated the association of BMI as a continuous
variable with major renal events using piece-wise linear
splines with knots at 18.5, 25, 30, 35, 40, and 45 kg/m2,
and a reference value at 21 kg/m2. The hazard ratio for
major renal events associated with each single additional
unit of BMI above 25 kg/m2 was also estimated.
Sensitivity analyses were performed to test the associa-
tion of BMI categories with the risk of major renal events:
(i) in different groups of randomised study treatment
(standard and intensive glucose control; placebo and
perindopril-indapamide) considered separately; (ii) in
different CKD stages (stage 1 [eGFR ≥ 90 mL/min/1.73
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m2]; stage 2 [≥60 to <90], and stage 3 [<60]); (iii) after
treating non-renal death as a competing risk using the
Fine and Gray method18; (iv) in participants who did not
change their BMI category during follow-up; (v) the
association of BMI categories with the risk of new
microalbuminuria in patients with normoalbuminuria at
baseline; and (vi) after including patients with under-
weight, who were otherwise omitted.
Statistical analyses were performed using SAS software,
version 9.3 (SAS Institute, www.sas.com) and Stata soft-
ware version 13 (StataCorp., www.stata.com). A
p-value< 0.05 was considered signiﬁcant.
Results
Baseline characteristics by BMI categories
Among 10,537 participants investigated, 58% were men,
and 38, 43, and 19% were from Asia, Established market
economies, and Eastern Europe, respectively (Table 1).
Their mean (SD) age and duration of diabetes were 66(6)
and 8(6) years, respectively, and their mean HbA1c was
7.5 (1.5)%. Mean (SD) BMI at baseline was 28(5) kg/m2,
and 2894 (27%), 4340 (41%), 2265 (22%), 744 (7%) and 294
(3%) patients, respectively, were in the normal weight,
overweight and obesity grades 1, 2 and 3 categories. Mean
eGFR was 75(17) mL/min/1.73 m2, and 2341 (22%), 5952
(57%) and 2244 (21%) were categorised as CKD stages 1,
2, and 3, respectively. Median urinary ACR was 15(7–40)
mg/g, with 7312 (69%), 2824 (27%) and 401 (4%) in the
normo-albuminuric, micro-albuminuric and macro-
albuminuric ranges.
Compared to those with normal weight, patients
with obesity were more frequently from established
market economies, had a shorter duration of diabetes, and
greater systolic blood pressure, and serum triglycerides
concentration. They were more likely to use anti-
hypertensive and lipid lowering treatments, and to have
ever smoked.
Risk of major renal events during follow-up by BMI
categories
Major renal events occurred in 487 (4.6%) participants
during a median duration of follow-up of 5.0 (inter-
quartile interval: 4.5–5.0) years. Patients who developed
major renal events during follow-up, compared to those
who did not, were more frequently men, had a longer
duration of diabetes at baseline, higher systolic blood
pressure, HbA1c, and urinary ACR levels, had a lower
eGFR, and were more likely to use antihypertensive and
lipid lowering drugs (Supplemental Table S1). Major renal
events occurred in 144 (5.0%), 181 (4.2%), 96 (4.2%), 43
(5.8%), and 23 (7.8%) participants with normal weight,
overweight, and obesity grades 1, 2 and 3, respectively
(Table 2). The risk of major renal events increased gra-
dually across increasing BMI categories, and the highest
risk was observed in patients with severe obesity. Adjusted
HRs (95% CIs) from model 1, compared to normal weight,
were: overweight: 0.91 (0.72–1.15), obesity grade 1: 1.03
(0.77–1.37), grade 2: 1.42 (0.98–2.07), and grade 3: 2.16
(1.34–3.48, p for trend= 0.006). Very similar results were
observed when additional adjustments, including med-
iating factors, were included (model 2)—as was the case
for the remaining analyses (results not shown). The same
pattern was seen when BMI was ﬁtted as a continuous
variable (Fig. 1). Above 25 kg/m2, the association of BMI
with major renal events appeared to be log-linear, and
each additional unit was associated with 4(1–6)%
increased risk (p= 0.002).
Risk of secondary endpoints during follow-up according to
BMI categories at baseline
New cases of microalbuminuria, macroalbuminuria,
and doubling of creatinine, ESRD or renal death occurred
during follow-up in 2730 (25.9%), 389 (3.5%) and 162
(1.5%) participants, respectively. The risk of new micro-
albuminuria or macroalbuminuria increased gradually
across increasing BMI categories (Table 3). The risk
of doubling of creatinine, ESRD or renal death seems to
be higher in patients with obesity stages 2 and 3, but
the test for trend was non-signiﬁcant. Each additional unit
of BMI over 25 kg/m2 increased the risk of micro-
albuminuria (p= 0.0008), macroalbuminuria (p= 0.004),
and doubling of creatinine, ESRD or renal death (p=
0.008) by 2(1–3), 4(1–6), and 5(1–10)%, respectively (using
model 1).
Sensitivity analyses
The associations of BMI categories with the risk of
major renal events were compared in different groups of
study treatments (Table 4, p for interaction between trend
in BMI and glucose lowering control= 0.14 and p for
interaction between trend in BMI and blood pressure
treatment= 0.96), as well as in different baseline CKD
stages (p for interaction= 0.14, Supplemental Table S2)
and remained signiﬁcant after treating non-renal death as
a competing risk (p for trend= 0.01, Supplemental
Table S3). During follow-up, 7103 (67%) participants
maintained the same BMI categories as at baseline (Sup-
plemental Table S4). When we considered only these
participants, BMI categories remained signiﬁcantly asso-
ciated with major renal events (p for trend= 0.002, Sup-
plemental Table S5). Similarly, the association of BMI
categories with increasing risk of new microalbuminuria
remained signiﬁcant (p for trend= 0.02) in patients with
normoalbuminuria at baseline (Supplemental Table S6).
Finally, when we considered the entire cohort, under-
weight was associated with a higher risk of major renal
events compared to normal weight (HR 2.17, 95% CI
1.01–4.67) (using model 1).
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Discussion
In the current investigation, we evaluated the effect of
BMI at baseline on the 5-year risk of major renal events in
patients with type 2 diabetes. Above 25 kg/m2, the risk of
major renal events increased progressively through BMI
categories: on average, each 1 unit higher BMI increased
this risk by 4%. The increased risk of major renal events
was independent of putative risk factors and was observed
even after allowing for the competing risk of non-renal
death. It was comparable in participants randomly
assigned to either standard or intensive glucose control,
and to placebo or perindopril-indapamide. Similar asso-
ciations were also observed when we considered only
participants who remained in the same BMI categories
during follow-up.
Only a few prospective studies have examined the
relationship between BMI and renal events separately
among people who have already developed type 2 dia-
betes, and these have reported a range of ﬁndings9,19,20.
One of the larger studies conducted in 5829 Chinese
patients with type 2 diabetes (mean %HbA1< 8) found an
inverse association between BMI and CKD. However,
these analyses adjusted for risk factors on the causal
pathway between BMI and CKD, including blood pres-
sure, albuminuria, diabetic characteristics, and other traits
of metabolic syndrome (e.g. central obesity), and this
adjustment may have distorted aetiological associations20.
Our own larger study of 10,537 patients with type 2 dia-
betes provides clear evidence for an increased risk of
major renal events with increasing BMI over 25 kg/m2, inTa
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Fig. 1 Hazard ratios for a major renal event by BMI splines at
baseline. Multi-adjusted hazard ratios (solid line) and 95% conﬁdence
intervals (shaded region) for major renal events during follow-up
according to baseline BMI as a continuous variable with a reference
value at 21 kg/m2 (diamond). Analyses were adjusted for baseline age,
sex, region of origin, prior cardiovascular disease, estimated
glomerular ﬁltration rate (and its square), urinary albumin to creatinine
ratio, history of ever smoking, and study allocations
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Cox models including BMI both as a categorical and as a
continuous variable. The highest risk was observed in
patients with morbid obesity.
Despite little apparent cross-sectional association between
baseline BMI and baseline urinary ACR in our study, there
was a clear positive association between BMI and develop-
ment of new cases of microalbuminuria and macro-
albuminuria, and these hazards were similar in size to the
trend toward association between BMI and doubling of
creatinine, ESRD or death. Furthermore, each additional
unit of BMI over 25 kg/m2 increased these endopints by 2,
4, and 5%, respectively. A key mechanism for obesity-
associated albuminuria is intraglomerular hypertension,
which increases renal blood ﬂow and fractional urinary
albumin clearance21–24. The consequent mechanical stress
results in glomerular enlargement (hypertrophy) and an
increased distance between the neighbouring podocytes,
damaging a key cellular layer of the glomerular ﬁltration
barrier25 and perhaps causing podocyte death with focal
segmental glomerulosclerosis26–28. Randomisation to peri-
ndopril+ indapamide in ADVANCE reduced total renal
events (major renal events plus new microalbuminuria) by
21% (relative risk 0.79, 0.73–0.85)15. However, in our sub-
group analyses, we found BMI–major renal events associa-
tions were not modiﬁed by allocated to perindopril+
indpamide, which is consistent with a hypothesis that gen-
eral adiposity may affect renal risk by mechanisms in
addition to the haemodynamic stress of glomerular
hyperﬁltration.
Hyperglycaemia has been suggested as a metabolic
podocyte stressor25. An inverse association between high
insulin sensitivity (estimated by euglycemic clamp) and
impaired renal function in a community-based cohort
has been reported29, and pre-diabetes has been associated
with directly measured evidence of hyperﬁltration inde-
pendent of BMI7. However, our subgroup analyses sug-
gested that the BMI–major renal events association was
not signiﬁcantly modiﬁed by glycaemic control allocation
(average HbA1c difference 0.7%), despite the inverse
relationship between HbA1c and weight30. Another
mechanism by which adipose tissue may cause kidney
disease is the visceral fat deposition in the renal sinus,
which may compress the main renal artery and vein31–33,
but measurements relevant to these mechanisms were
not measured in this study.
Nevertheless, our ﬁndings are consistent with reports
that weight loss may protect against the development of
renal complications in overweight or obese individuals
with type 2 diabetes. The Look AHEAD (Action for
Health in Diabetes) trial showed that intensive lifestyle
intervention, compared to standard education, resulted in
8% weight loss (on average 4 kg) and a consequent 31%
reduction (hazard ratio 0.69 [0.55–0.87]) in “very-high-risk
CKD” (based in KDIGO risk charts)34. Weight loss mayTa
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also be one of the mechanisms by which sodium-glucose
co-transporter 2 inhibitors or analogues of glucagon-like
peptide 1 reduce renal risk35–37. Lastly, bariatric surgery
has been associated with an improvement in renal func-
tion38–40. Regardless of the mechanism, higher risk with
obesity suggests there may be greater absolute beneﬁt from
attention to all risk factors among patients with obesity and
diabetes at risk for CKD progression.
The present investigation’s key strength was its com-
prehensive clinical and biological characterisation of
participants, and 5 years of prospective follow-up
including pre-speciﬁed renal outcomes conﬁrmed by an
independent adjudication committee13. However, it is
possible that the number of major renal events may have
been insufﬁciently large to identify important differences
between the randomised groups. Also, ADVANCE did
not collect detailed data on body fat distribution, so that
important differences between body-mass composition
between participants could not be assessed for its rele-
vance to major renal events. Furthermore, creatinine
determinations were not isotope dilution mass spectro-
metry (IDMS) traceable in the ADVANCE trial as all
participants were enroled before the international
recommendations for IDMS alignment41,42.
In conclusion, obesity at different stages was an inde-
pendent predictor of major renal events in patients with
type 2 diabetes. Our ﬁndings encourage comprehensive
and motivated weight loss programmes for improving the
prevention of the development and progression of kidney
complications in patients with both type 2 diabetes and
obesity.
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